Share Price and Basic Stock Data
Last Updated: October 18, 2025, 8:11 pm
| PEG Ratio | -1.92 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dipna Pharmachem Ltd operates in the pharmaceuticals sector, with a current share price of ₹22.8 and a market capitalization of ₹54.7 Cr. The company has witnessed notable revenue growth, with sales recorded at ₹74 Cr in both September 2023 and March 2024, up from ₹49 Cr in September 2022. This upward trend in sales aligns with a broader industry recovery post-pandemic. The total sales for the fiscal year ending March 2025 stood at ₹125 Cr, reflecting a significant increase from ₹100 Cr in March 2023. The operating profit margin (OPM) has remained stable at 2% for most recent quarters, with a slight improvement expected in the future as the company aims for a higher margin of 6% in March 2025. However, the company’s overall sales performance still appears lower compared to industry leaders, indicating room for growth and increased market penetration. The absence of other income suggests a reliance on core pharmaceutical operations for revenue generation.
Profitability and Efficiency Metrics
Profitability metrics for Dipna Pharmachem show a mixed performance. The net profit for the latest reported quarter was ₹1 Cr, maintaining a consistent level since March 2023. However, the return on equity (ROE) stood at a modest 2.55%, while the return on capital employed (ROCE) was slightly higher at 6.64%. These figures indicate that while the company is generating profits, they are not commensurate with the capital invested, highlighting inefficiencies in asset utilization. The interest coverage ratio at 1.72x suggests that the company can cover its interest obligations, but it remains on the lower side, indicating potential vulnerabilities in cash flow management. The cash conversion cycle, which is reported at -20 days, indicates that the company is efficiently managing its receivables and payables, allowing for quicker cash recovery, but this may also reflect aggressive credit policies that could pose risks in times of economic downturn.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dipna Pharmachem reveals a cautious approach to financial management. The company reported total borrowings of ₹17 Cr against reserves of ₹14 Cr, leading to a debt-to-equity ratio of 0.51, which is relatively healthy compared to industry norms. The current ratio is at 1.60, suggesting that the company has sufficient assets to cover its short-term liabilities. However, the low price-to-book value ratio of 0.60x indicates that the market may undervalue the company’s equity relative to its book value, which could reflect concerns over future profitability. Additionally, the operating profit margin remains low at 2%, which could limit the company’s ability to reinvest in growth initiatives. The total assets stood at ₹132 Cr, with no significant fixed assets, indicating a business model that is likely service-oriented rather than capital-intensive.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dipna Pharmachem highlights a significant shift towards public ownership, with promoters holding just 9.98% as of March 2024, down from 66.56% in September 2022. This change suggests a dilution of control by insiders and a growing confidence from public investors, who now own 90.01% of the company. The total number of shareholders has also increased to 1,997, indicating rising interest and possibly enhanced liquidity in the stock. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) might reflect a cautious stance from larger investment entities, potentially due to the company’s modest profitability metrics and low ROE. This shift in the shareholding pattern could either signal a positive sentiment from retail investors or concerns over the long-term strategic direction of the company.
Outlook, Risks, and Final Insight
If margins sustain their positive trajectory and the company successfully navigates its operational challenges, there could be potential for enhanced profitability in the coming years. However, risks remain, including the low ROE and ROCE, which could impede growth if not addressed. Additionally, the heavy reliance on public ownership could lead to volatility if investor sentiment shifts. Furthermore, sustaining the negative cash conversion cycle may pose risks if credit policies tighten or demand slows. The company also faces competitive pressures in the pharmaceutical sector, which could impact its market share. Overall, while there are opportunities for growth, particularly if the company can improve its operational efficiency and profitability metrics, the management will need to address existing weaknesses to enhance investor confidence moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dipna Pharmachem Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 44 | 49 | 74 | 74 | 90 | 91 | 34 |
| Expenses | 28 | 42 | 48 | 73 | 73 | 88 | 89 | 32 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| OPM % | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Tax % | 25% | 26% | 26% | 27% | 27% | 21% | 26% | 34% |
| Net Profit | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
| EPS in Rs | 33.00 | 84.00 | 0.13 | 0.24 | 0.24 | 0.20 | 0.14 | 0.27 |
Last Updated: July 16, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Sep 2024) to 34.00 Cr., marking a decrease of 57.00 Cr..
- For Expenses, as of Mar 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 89.00 Cr. (Sep 2024) to 32.00 Cr., marking a decrease of 57.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Mar 2025, the value is 6.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Sep 2024) to 6.00%, marking an increase of 4.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Mar 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Sep 2024) to 34.00%, marking an increase of 8.00%.
- For Net Profit, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.27. The value appears strong and on an upward trend. It has increased from 0.14 (Sep 2024) to 0.27, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:29 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 142% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: July 25, 2025, 1:26 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 |
Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
- For Reserves, as of Mar 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 14.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Mar 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 19.00 Cr. (Mar 2024) to 17.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 77.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2024) to 77.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 132.00 Cr.. The value appears to be improving (decreasing). It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2024) to 132.00 Cr., marking a decrease of 1.00 Cr..
However, the Borrowings (17.00 Cr.) are higher than the Reserves (14.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -6.00 | -10.00 | -12.00 | -8.00 | -14.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Diluted EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Cash EPS (Rs.) | 0.40 | 0.45 | 0.77 | 335.17 | 8.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Revenue From Operations / Share (Rs.) | 51.95 | 68.34 | 83.48 | 20787.26 | 8857.11 |
| PBDIT / Share (Rs.) | 1.43 | 1.43 | 1.96 | 644.23 | 118.66 |
| PBIT / Share (Rs.) | 1.43 | 1.42 | 1.95 | 642.46 | 116.60 |
| PBT / Share (Rs.) | 0.59 | 0.59 | 1.15 | 449.80 | 15.71 |
| Net Profit / Share (Rs.) | 0.40 | 0.45 | 0.76 | 333.40 | 6.91 |
| PBDIT Margin (%) | 2.75 | 2.08 | 2.35 | 3.09 | 1.33 |
| PBIT Margin (%) | 2.75 | 2.07 | 2.33 | 3.09 | 1.31 |
| PBT Margin (%) | 1.13 | 0.86 | 1.38 | 2.16 | 0.17 |
| Net Profit Margin (%) | 0.77 | 0.66 | 0.91 | 1.60 | 0.07 |
| Return on Networth / Equity (%) | 2.53 | 2.89 | 3.74 | 67.11 | 4.23 |
| Return on Capital Employeed (%) | 7.25 | 6.82 | 6.06 | 44.39 | 9.58 |
| Return On Assets (%) | 0.73 | 0.81 | 1.17 | 3.22 | 0.09 |
| Long Term Debt / Equity (X) | 0.23 | 0.33 | 0.58 | 1.91 | 6.44 |
| Total Debt / Equity (X) | 0.44 | 0.51 | 0.65 | 5.86 | 21.74 |
| Asset Turnover Ratio (%) | 0.94 | 1.56 | 1.76 | 2.38 | 1.43 |
| Current Ratio (X) | 1.56 | 1.60 | 1.99 | 1.16 | 1.21 |
| Quick Ratio (X) | 1.23 | 1.15 | 1.50 | 0.95 | 0.85 |
| Inventory Turnover Ratio (X) | 3.85 | 5.84 | 0.00 | 10.03 | 4.90 |
| Interest Coverage Ratio (X) | 1.71 | 1.72 | 2.46 | 3.34 | 1.18 |
| Interest Coverage Ratio (Post Tax) (X) | 1.48 | 1.54 | 1.95 | 2.73 | 1.07 |
| Enterprise Value (Cr.) | 51.18 | 28.22 | 25.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.17 | 0.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | 14.85 | 8.22 | 10.74 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| Price / BV (X) | 0.89 | 0.60 | 0.61 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.04 | 0.06 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
- For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
- For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
- For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
- Net Profit Margin: 0.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.25% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.53% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.48
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 52.8 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055 | info@dipnapharmachem.com http://www.dipnapharmachem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Keyur Dipakkumar Shah | Managing Director |
| Ms. Dipna Keyur Shah | Non Executive Director |
| Mr. Nirav Soni | Non Executive Director |
| Mr. Nandish Shaileshbhai Jani | Independent Director |
| Mr. Parin Bhavsar | Independent Director |
FAQ
What is the intrinsic value of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd's intrinsic value (as of 18 October 2025) is 17.58 which is 17.46% lower the current market price of 21.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 51.2 Cr. market cap, FY2025-2026 high/low of 26.3/6.40, reserves of ₹14 Cr, and liabilities of 132 Cr.
What is the Market Cap of Dipna Pharmachem Ltd?
The Market Cap of Dipna Pharmachem Ltd is 51.2 Cr..
What is the current Stock Price of Dipna Pharmachem Ltd as on 18 October 2025?
The current stock price of Dipna Pharmachem Ltd as on 18 October 2025 is 21.3.
What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dipna Pharmachem Ltd stocks is 26.3/6.40.
What is the Stock P/E of Dipna Pharmachem Ltd?
The Stock P/E of Dipna Pharmachem Ltd is 52.8.
What is the Book Value of Dipna Pharmachem Ltd?
The Book Value of Dipna Pharmachem Ltd is 16.0.
What is the Dividend Yield of Dipna Pharmachem Ltd?
The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.
What is the ROCE of Dipna Pharmachem Ltd?
The ROCE of Dipna Pharmachem Ltd is 6.64 %.
What is the ROE of Dipna Pharmachem Ltd?
The ROE of Dipna Pharmachem Ltd is 2.55 %.
What is the Face Value of Dipna Pharmachem Ltd?
The Face Value of Dipna Pharmachem Ltd is 10.0.